» Articles » PMID: 21862310

Strategies for Extended Serum Half-life of Protein Therapeutics

Overview
Publisher Elsevier
Specialty Biotechnology
Date 2011 Aug 25
PMID 21862310
Citations 217
Authors
Affiliations
Soon will be listed here.
Abstract

With a growing number of protein therapeutics being developed, many of them exhibiting a short plasma half-life, half-life extension strategies find increasing attention by the biotech and pharmaceutical industry. Extension of the half-life can help to reduce the number of applications and to lower doses, thus are beneficial for therapeutic but also economic reasons. Here, a comprehensive overview of currently developed half-life extension strategies is provided including those aiming at increasing the hydrodynamic volume of a protein drug but also those implementing recycling processes mediated by the neonatal Fc receptor.

Citing Articles

Purification of a Fc-Fusion Protein with [Bathophenathroline:metal] Complexes.

Withanage T, Alcalay R, Krichevsky O, Wachtel E, Mazor O, Patchornik G Antibodies (Basel). 2025; 14(1).

PMID: 39982226 PMC: 11843901. DOI: 10.3390/antib14010011.


Enzymatic Desialylation Enables Reliable Charge Variant Characterization of Highly Glycosylated and Sialylated Fc Fusion Proteins.

Wen X, Liu A, Song J, Leng C, Wang J, Russo B ACS Pharmacol Transl Sci. 2025; 8(2):394-408.

PMID: 39974635 PMC: 11833721. DOI: 10.1021/acsptsci.4c00460.


Immunoinformatic approach to the design of a novel multi-epitope vaccine against fused to human IgG-Fc.

Fadaie M, Shahmoradi Z, Khanahmad H Res Pharm Sci. 2025; 19(6):729-745.

PMID: 39911897 PMC: 11792711. DOI: 10.4103/RPS.RPS_145_24.


Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein.

Bai S, Cui Y, Liao Q, Yi H, Liao Z, Zhang G Viruses. 2025; 17(1).

PMID: 39861905 PMC: 11768982. DOI: 10.3390/v17010116.


Revolutionizing Heart Failure Therapy: Harnessing IVT mRNA and Fusion Protein Technology to Prolong rhBNP Half-Life.

Guo Y, Sun T, Li M, Chen Z, Liu Y, Luo X Pharm Res. 2025; 42(1):137-149.

PMID: 39806211 PMC: 11785693. DOI: 10.1007/s11095-024-03807-x.